Rallybio (RLYB) Competitors

Rallybio logo
$15.29 -0.14 (-0.91%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$15.24 -0.05 (-0.33%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RLYB vs. AUTL, IRON, AGEN, ELYM, and XFOR

Should you buy Rallybio stock or one of its competitors? Rallybio's main competitors and comparable companies include Autolus Therapeutics (AUTL), Disc Medicine (IRON), Agenus (AGEN), Eliem Therapeutics (ELYM), and X4 Pharmaceuticals (XFOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rallybio compare to Autolus Therapeutics?

Rallybio (NASDAQ:RLYB) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Rallybio has higher earnings, but lower revenue than Autolus Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rallybio$860K95.65-$8.98M-$3.67N/A
Autolus Therapeutics$75.39M3.85-$287.53M-$0.97N/A

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 10.3% of Rallybio shares are owned by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Autolus Therapeutics has a consensus price target of $10.00, indicating a potential upside of 817.43%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Rallybio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rallybio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Autolus Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.88

Autolus Therapeutics has a net margin of -186.37% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -31.44% beat Autolus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rallybio-911.07% -31.44% -29.89%
Autolus Therapeutics -186.37%-263.25%-48.04%

In the previous week, Autolus Therapeutics had 2 more articles in the media than Rallybio. MarketBeat recorded 6 mentions for Autolus Therapeutics and 4 mentions for Rallybio. Autolus Therapeutics' average media sentiment score of 0.57 beat Rallybio's score of 0.23 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rallybio
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Autolus Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Rallybio has a beta of -0.73, indicating that its share price is 173% less volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.32, indicating that its share price is 132% more volatile than the broader market.

Summary

Autolus Therapeutics beats Rallybio on 12 of the 17 factors compared between the two stocks.

How does Rallybio compare to Disc Medicine?

Rallybio (NASDAQ:RLYB) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Rallybio has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rallybio$860K95.65-$8.98M-$3.67N/A
Disc MedicineN/AN/A-$212.18M-$6.34N/A

Rallybio has a beta of -0.73, meaning that its share price is 173% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Disc Medicine has a consensus price target of $124.18, indicating a potential upside of 62.18%. Given Disc Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Disc Medicine is more favorable than Rallybio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rallybio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.79

Disc Medicine has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -31.44% beat Disc Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Rallybio-911.07% -31.44% -29.89%
Disc Medicine N/A -36.33%-32.50%

90.3% of Rallybio shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 10.3% of Rallybio shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Disc Medicine had 2 more articles in the media than Rallybio. MarketBeat recorded 6 mentions for Disc Medicine and 4 mentions for Rallybio. Disc Medicine's average media sentiment score of 0.75 beat Rallybio's score of 0.23 indicating that Disc Medicine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rallybio
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Disc Medicine
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Rallybio beats Disc Medicine on 8 of the 15 factors compared between the two stocks.

How does Rallybio compare to Agenus?

Rallybio (NASDAQ:RLYB) and Agenus (NASDAQ:AGEN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Rallybio has a beta of -0.73, indicating that its share price is 173% less volatile than the broader market. Comparatively, Agenus has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market.

Agenus has a net margin of 22.10% compared to Rallybio's net margin of -911.07%. Agenus' return on equity of -27.16% beat Rallybio's return on equity.

Company Net Margins Return on Equity Return on Assets
Rallybio-911.07% -31.44% -29.89%
Agenus 22.10%-27.16%26.91%

Agenus has a consensus price target of $25.00, suggesting a potential upside of 302.58%. Given Agenus' stronger consensus rating and higher probable upside, analysts plainly believe Agenus is more favorable than Rallybio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rallybio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Agenus
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Rallybio had 4 more articles in the media than Agenus. MarketBeat recorded 4 mentions for Rallybio and 0 mentions for Agenus. Agenus' average media sentiment score of 0.91 beat Rallybio's score of 0.23 indicating that Agenus is being referred to more favorably in the news media.

Company Overall Sentiment
Rallybio Neutral
Agenus Positive

Agenus has higher revenue and earnings than Rallybio. Rallybio is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rallybio$860K95.65-$8.98M-$3.67N/A
Agenus$114.20M2.46$120K$0.669.41

90.3% of Rallybio shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 10.3% of Rallybio shares are held by insiders. Comparatively, 6.5% of Agenus shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Agenus beats Rallybio on 12 of the 16 factors compared between the two stocks.

How does Rallybio compare to Eliem Therapeutics?

Rallybio (NASDAQ:RLYB) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Rallybio has a beta of -0.73, suggesting that its share price is 173% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market.

Eliem Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -31.44% beat Eliem Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rallybio-911.07% -31.44% -29.89%
Eliem Therapeutics N/A -47.03%-45.97%

In the previous week, Rallybio had 4 more articles in the media than Eliem Therapeutics. MarketBeat recorded 4 mentions for Rallybio and 0 mentions for Eliem Therapeutics. Rallybio's average media sentiment score of 0.23 beat Eliem Therapeutics' score of 0.00 indicating that Rallybio is being referred to more favorably in the media.

Company Overall Sentiment
Rallybio Neutral
Eliem Therapeutics Neutral

Rallybio has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rallybio$860K95.65-$8.98M-$3.67N/A
Eliem TherapeuticsN/AN/A-$35.12M-$0.53N/A

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 10.3% of Rallybio shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rallybio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Eliem Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Rallybio beats Eliem Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Rallybio compare to X4 Pharmaceuticals?

Rallybio (NASDAQ:RLYB) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

X4 Pharmaceuticals has a consensus price target of $11.25, indicating a potential upside of 264.08%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Rallybio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rallybio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
X4 Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Rallybio has higher earnings, but lower revenue than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rallybio$860K95.65-$8.98M-$3.67N/A
X4 Pharmaceuticals$35.11M8.73-$79.20M-$0.67N/A

Rallybio has a beta of -0.73, suggesting that its share price is 173% less volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 10.3% of Rallybio shares are owned by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

X4 Pharmaceuticals has a net margin of -474.74% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -31.44% beat X4 Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rallybio-911.07% -31.44% -29.89%
X4 Pharmaceuticals -474.74%-49.62%-30.80%

In the previous week, Rallybio had 3 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 4 mentions for Rallybio and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.41 beat Rallybio's score of 0.23 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rallybio
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
X4 Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

X4 Pharmaceuticals beats Rallybio on 8 of the 15 factors compared between the two stocks.

Get Rallybio News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RLYB vs. The Competition

MetricRallybioBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$83.05M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-4.1726.6634.3428.00
Price / Sales95.6515.788.485.70
Price / CashN/A22.9521.0121.90
Price / Book0.894.184.463.72
Net Income-$8.98M-$24.15M$3.52B$393.10M
7 Day Performance-3.23%-7.77%-5.93%-5.76%
1 Month Performance-6.08%-5.94%-4.58%-7.14%
1 Year Performance205.12%-8.09%-1.94%-7.46%

Rallybio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RLYB
Rallybio
1.0791 of 5 stars
$15.29
-0.9%
N/A+209.7%$83.05M$860KN/A6
AUTL
Autolus Therapeutics
3.4898 of 5 stars
$1.28
-3.4%
$10.00
+684.3%
-18.7%$339.36M$117.39MN/A752
IRON
Disc Medicine
3.5839 of 5 stars
$86.04
+1.7%
$124.18
+44.3%
-14.6%$329.55MN/AN/A165
AGEN
Agenus
2.7467 of 5 stars
$7.25
+3.2%
$25.00
+245.1%
+43.8%$328.06M$114.20M10.9981
ELYM
Eliem Therapeutics
N/A$11.01
+7.0%
N/A+423.2%$327.57MN/AN/A9

Related Companies and Tools


This page (NASDAQ:RLYB) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners